Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2924675 | 0.86 | CCR2 (0.42) | CCR2KMT2ACACNA1HCACNA1BLIMK2 | |
| SCHEMBL2924677 | 0.86 | CCR2 (0.42) | CCR2KMT2ACACNA1HCACNA1BLIMK2 | |
| SCHEMBL3754021 | 0.86 | CCR2 (0.42) | CCR2KMT2ACACNA1HCACNA1BLIMK2 | |
| SCHEMBL3277546 | 0.86 | CCR2 (0.47) | CCR2KMT2ACACNA1HCACNA1BCNR1 | |
| SCHEMBL2905205 | 0.84 | CCR2 (0.42) | CCR2KMT2ACACNA1HCACNA1BLIMK2 | |
| SCHEMBL2905209 | 0.84 | CCR2 (0.42) | CCR2KMT2ACACNA1HCACNA1BLIMK2 | |
| SCHEMBL3751375 | 0.84 | CCR2 (0.42) | CCR2KMT2ACACNA1HCACNA1BLIMK2 | |
| SCHEMBL3149091 | 0.84 | DRD2 (0.48) | CCR2 | |
| SCHEMBL3149096 | 0.84 | DRD2 (0.48) | CCR2 | |
| SCHEMBL2897997 | 0.81 | CHRM4 (0.44) | CCR2KMT2AMEN1TDP1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298299-A1 | NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298299-A1 | NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, NPBWR1 | CCR2 611/4885KMT2A 4569/4885CACNA1H 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.